SeaStar Medical DSMB recommends continue NEUTRALIZE-AKI trial; enrollment target raised to 339

SeaStar Medical Holding Corp

DSMB reports zero device-related safety issues in first 100 patients; recommends continuation of pivotal AKI trial.
Enrollment target increased from 200 to 339 patients to meet statistical power; 137 patients enrolled to date.
Estimated enrollment completion near end of 2026 based on current rate and new site additions.
QUELIMMUNE pediatric registry shows 75% 28-day survival and no device-related safety events in first 20 patients.
Company highlights potential clinical benefit signal; plans to manage capital to support milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.